Curative Effect Observation Of Combination Of Endostatin With Pemetrexed、Lobaplatin In The Treatment Of Advanced Recurrent Lung Adenocarcinoma

Objective To study the clinical effects of endostatin(endostar)with pemetrexed 、lobaplatin on patients with advanced recurrent lung adenocarcinoma.It includes the recent curative effects of RR、DCR,the forward effects of PFS、OS、1 year survival,the associated myelosuppression,and the incidence of the impairment of liver and kidney function.Methods 55 cases of advanced recurrent lung adenocarcinoma patients were randomly divided into 2 groups.research group: 27 cases received endostatin with pemetrexed and Lobaplatin;control group : 28 cases received pemetrexed with Lobaplatin.The two groups were treated for 2 to 6 cycles,and evaluation of treatments was performed every two cycles.Reord the RR、DCR、PFS、OS、1 year survival,and the incidence of the adverse reaction.Collect the case information of all the patients,then use the SPSS 19.0 statistical software to analyze the data,and P < 0.05 is statistically significant.Results 1.The short-term effects : there is no CR in the two groups,the total effective rates(RR)in the research and control group were 22.2% and 14.3%,it was not significantly different(P>0.05).The disease control rate(DCR)were 92.6% and 71.4%,the difference was statistically significant(P<0.05).2.The long-term effects : the PFS、OS even the 1 year survival of the two groups were not significantly different(P>0.05).3.Adverse reaction: for neutropenia,decrease of hemoglobin and platelet as well as white blood cells,and the impairment of liver and kidney function,there were no statistical differences(P>0.05)between two groups.But for gastrointestinal reactions,the research group was lighter than the control group,and the difference was statistically significant(P<0.05).Conclusion The research demonstrated that endostatin combined with pemetrexed and lobaplatin can improve advanced recurrent lung adenocarcinoma patients’ disease control rate(DCR),relieve nausea and vomiting and other gastrointestinal reactions,improve the quality of life,and do not increase other adverse effects such as myelosuppression and the impairment of liver and kidney function.